Pharvaris
PHVS
31.28
-0.38
-1.20%
Pharvaris
US · PHVS
#2729 by market cap
Listed 2021
31.28
-0.38
-1.20%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 668.12K | 2.33M | 5.50M | 18.35M | 29.34M | 31.34M | 47.12M | 45.34M |
| Research & development | 3.65M | 5.68M | 19.51M | 35.79M | 57.38M | 65.58M | 98.56M | 124.48M |
| Operating profit | -4.31M | -8.01M | -25.01M | -54.14M | -86.71M | -96.91M | -145.69M | -169.82M |
| Pretax profit | -4.31M | -8.03M | -26.07M | -42.66M | -75.65M | -99.83M | -132.40M | -173.71M |
| Tax | 0 | 0 | -83.25K | 70.12K | 679.09K | 1.05M | 1.83M | 1.99M |
| Net profit | -4.31M | -8.03M | -25.99M | -42.73M | -76.33M | -100.88M | -134.22M | -175.70M |
| Basic EPS | 0 | 0 | -1 | -1 | -2 | -3 | -2 | -3 |
| Diluted EPS | -0.14 | -0.25 | -0.85 | -1.40 | -2.27 | -2.63 | -2.48 | -2.97 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 10.77M | 9.85M | 13.46M | 14.11M | 15.79M | 17.66M |
| Research & development | 29.61M | 29.81M | 34.14M | 30.16M | 35.00M | 32.42M |
| Operating profit | -40.37M | -39.66M | -47.60M | -44.27M | -50.79M | -50.08M |
| Pretax profit | -45.28M | -37.32M | -45.08M | -38.93M | -47.24M | -47.20M |
| Tax | 202.78K | -181.47K | 1.66M | 273.11K | 602.20K | 214.52K |
| Net profit | -45.48M | -37.14M | -46.74M | -39.20M | -47.84M | -47.41M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.83 | -0.60 | -0.71 | -0.60 | -0.70 | -0.67 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 5.43M | 20.58M | 100.95M | 211.57M | 166.85M | 397.85M | 289.42M | 299.17M |
| Cash & ST investments | 5.39M | 20.33M | 98.63M | 209.35M | 161.84M | 391.23M | 280.73M | 291.68M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 5.43M | 20.60M | 101.10M | 212.09M | 167.73M | 398.69M | 291.37M | 301.45M |
| Total current liabilities | 481.34K | 1.92M | 5.31M | 6.99M | 18.22M | 14.60M | 22.97M | 29.60M |
| Short-term debt | -- | -- | -- | 99.43K | 187.40K | 195.34K | 222.43K | 200.21K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 481,340.00 | 1,924,130.00 | 5,313,789.00 | 7,136,995.00 | 18,473,953.00 | 14,646,062.00 | 23,614,024.00 | 30,180,665.00 |
| Total equity | 4.95M | 18.67M | 95.79M | 204.95M | 149.26M | 384.05M | 267.76M | 271.27M |
| Retained earnings | -10.45M | -18.47M | -44.46M | -87.57M | -164.19M | -265.92M | -402.26M | -579.60M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 208.17M | 337.19M | 299.17M | 257.68M | 326.88M | 293.21M |
| Cash & ST investments | 199.57M | 329.29M | 291.68M | 246.96M | 318.28M | 282.73M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 209.81M | 338.90M | 301.45M | 259.79M | 328.67M | 295.06M |
| Total current liabilities | 25.00M | 26.21M | 29.60M | 22.92M | 27.38M | 29.66M |
| Short-term debt | 161.54K | 137.62K | 200.21K | 206.31K | 192.40K | 173.66K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 25,474,434.00 | 26,655,561.00 | 30,180,665.00 | 23,455,647.00 | 27,856,887.00 | 30,089,488.00 |
| Total equity | 184.34M | 312.24M | 271.27M | 236.33M | 300.81M | 264.97M |
| Retained earnings | -494.94M | -532.38M | -579.60M | -619.54M | -668.58M | -716.58M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -3.92M | -6.68M | -21.50M | -44.60M | -67.16M | -93.05M | -120.13M | -137.07M |
| Depreciation & amortization | 0 | 549 | 7.40K | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K |
| Free cash flow | -3.92M | -6.69M | -21.54M | -44.73M | -67.29M | -93.14M | -120.67M | -137.24M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 4.51M | 22.47M | 102.51M | 156.83M | 9.61M | 342.91M | 2.24M | 171.74M |
| Ending cash balance | 5.39M | 20.33M | 98.63M | 209.35M | 161.84M | 391.23M | 280.73M | 291.68M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | -29.98M | -30.67M | -37.95M | -48.77M | -37.80M | -42.22M |
| Depreciation & amortization | 103.03K | 105.15K | 104.87K | 104.73K | 179.30K | 92.39K |
| Free cash flow | -29.96M | -30.69M | -37.95M | -48.82M | -37.83M | -42.22M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 370 | 171.37M | 337.34K | 0 | 113.13M | 6.22M |
| Ending cash balance | 199.57M | 329.29M | 291.68M | 246.96M | 318.28M | 282.73M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -89.78 | -67.95 | -45.41 | -28.42 | -43.10 | -37.83 | -41.18 | -65.19 |
| ROA %i | -84.33 | -61.67 | -42.71 | -27.29 | -40.19 | -35.62 | -38.90 | -59.27 |
| ROIC %i | -89.78 | -67.95 | -45.24 | -28.37 | -43.01 | -37.78 | -41.11 | -64.99 |
| 5-year avg ROE %i | -- | -- | -- | -- | -54.93 | -44.54 | -39.19 | -43.14 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.29 | 10.70 | 19.00 | 30.28 | 9.16 | 27.25 | 12.60 | 10.11 |
| Quick ratioi | 11.24 | 10.67 | 18.67 | 30.07 | 8.90 | 26.86 | 12.35 | 10.01 |
| Debt / assetsi | -- | -- | 0.00 | 0.12 | 0.26 | 0.06 | 0.30 | 0.26 |
| LT debt / equityi | -- | -- | -- | 0.07 | 0.17 | 0.01 | 0.24 | 0.21 |
| Interest coveragei | -- | -- | -280.92 | -- | -4,696.51 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -65.09 | -53.76 | -65.19 | -73.02 | -70.46 | -62.78 |
| ROA %i | -59.93 | -50.22 | -59.27 | -66.38 | -63.48 | -57.16 |
| ROIC %i | -64.99 | -53.70 | -64.99 | -72.79 | -70.27 | -62.65 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.33 | 12.86 | 10.11 | 11.24 | 11.94 | 9.89 |
| Quick ratioi | 8.09 | 12.67 | 10.01 | 10.99 | 11.82 | 9.73 |
| Debt / assetsi | 0.30 | 0.17 | 0.26 | 0.28 | 0.21 | 0.20 |
| LT debt / equityi | 0.26 | 0.14 | 0.21 | 0.23 | 0.16 | 0.16 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-11-20 20:01:10 · For reference only, not investment advice and not tailored to your situation.
Pharvaris discussion 0 comments